Welcome to BioArctic’s website. In order to optimize your use of our website we use cookies. If you want more information about our cookie policy, please read more here. By continuing, you agree to our use of cookies.
Sveriges Farmaceuter, a Swedish professional association for pharmacists, has chosen BioArctic’s CEO, Gunilla Osswald, as this year's recipient of the “Pharmacist of the Year” award. This ...
September is the official world Alzheimer's month, raising awareness for this disease globally. Approximately 50 million people suffer from dementia worldwide, and in Sweden, it afflicts ...
BioArctic is one of the finalists for the European Lifestars Awards in the category ”Deal of the Year (>£500m)” for its strategic collaboration with AbbVie ...
BioArctic's CEO, Gunilla Osswald, explains why in an interview with PharmaBoardroom https://pharmaboardroom.com/interviews/gunilla-osswald-ceo-bioarctic-sweden/
BioArctic’s CEO Gunilla Osswald speaking at the Dementia Forum X at the Royal Palace in Stockholm, participating in a global initiative to fight dementia.
Lars Lannfelt, Senior Professor of Geriatrics at Uppsala University, receives the Swedish Alzheimer's Foundation’s Grand Research Prize 2019 of SEK 2.5 million. He receives the award ...
For the ninth consecutive year, BioArctic invited students and teachers from the Rinkeby School in Stockholm and hosted a visit at the company. The Rinkeby School ...
The Allbright prize is presented annually to the Swedish listed company that has made the best progress in the area of gender equality during the past ...
BioArctic is pleased to announce that the company has been recognized with a highly commended accolade in the category EU Capital Market Transaction of the Year ...
Every fifth second someone in the world develops Alzheimer’s disease. There is a huge need for more research and effective treatments. September 2018 marks the seventh ...
At the most recent Assembly of the Academy seven individuals were elected members into the Royal Swedish Academy of Engineering Sciences. Gunilla Osswald was elected member ...
BioArctic will participate at the AAT-AD/PD Focus Meeting (Advances in Alzheimer Therapy - Alzheimer's Disease/Parkinson's Disease) on March 15-18, 2018 in Turin, Italy. At the conference ...
Every fifth second someone in the world develops Alzheimer’s disease. There is a huge need for more research and effective treatments. September 2017 marks the sixth ...
Election of new board member and new Chairman of the Board: The General Meeting resolved to appoint Eugen Steiner to new board member for the period ...
BioArctic will participate at the scientific meeting “20 years of alpha-synuclein in Parkinson’s Disease and related synucleinopathies: from the bedside to the bench and back to ...
BioArctic has received a grant of 200 000 SEK from Vinnova (Sweden’s Innovation Agency) and Medtech4Health for the company’s quality management system work. The grant is ...
BioArctic will participate at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria. The conference is focusing on mechanisms, clinical strategies, and promising ...
BioArctic is developing disease modifying treatment for Alzheimer’s disease. One major challenge is the limitations of biomarkers reflecting disease pathology, stage and severity. Thus, there is ...
Uppsala University and BioArctic have received a MSEK 5 grant from Vinnova for a collaborative research project concerning reduced costs and improved safety in immunotherapy for ...
Halfway through the world's largest research and innovation program, Horizon 2020, around 400 Swedish organizations have been granted over EUR 550 million in project funding to ...
BioArctic’s patent application encompassing treatment of Parkinson’s disease was granted in US 2016-04-19. The patent (US 9, 315, 569) covers treatment of Parkinson’s disease with an ...
BioArctic Neuroscience AB announces today that a new license agreement has been signed between BioArctic and the Japanese pharmaceutical company Eisai Co., Ltd.
In August 2015, VINNOVA announced that BioArctic Neuroscience AB together with the Ångström Laboratory, Department of Engineering Sciences, Uppsala University, and Psilox AB were granted extended ...
The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel disease modifying treatment for Parkinson´s disease with potential to improve the quality of life for ...
The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel disease modifying treatment for Parkinson´s disease with potential to improve the quality of life for ...
BioArctic Neuroscience has been nominated to SwedenBIO Award 2015. Each year SwedenBIO Award is awarded to a company that serves as a role model in the ...
BioArctic Neuroscience AB announces today that a new research agreement has been initiated between BioArctic and the Japanese pharmaceutical company Eisai. The research will lead to ...
On March 3rd 2015, the US patent office granted BioArctic a US patent (US 8, 968, 734 B2) covering therapeutic and diagnostic antibodies for Parkinson’s ...
The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel treatment for complete spinal cord injury. This project has received funding (6.4 M€) from the ...
In September 2014, VINNOVA announced that BioArctic Neuroscience AB together with the Ångström Laboratory, Department of Engineering Sciences, Uppsala University, and Psilox AB were granted up ...
The US patent office has granted BioArctic a US patent (US 8809506) covering therapeutic and diagnostic antibodies for Parkinson’s disease and Dementia with Lewy Bodies.
...
The US patent office has granted a BioArctic patent for protofibril-binding antibodies and their use in therapeutic and diagnostic methods for Parkinson's Disease, Dementia with Lewy ...
BioArctic´s mission is to provide new and effective treatments for patients with disorders in the Central Nervous System. The company has evolved in a very positive ...
BioArctic’s monoclonal antibody for Alzheimer’s disease, BAN2401, has entered the next clinical study after successfully passed phase IIa. Safety and tolerability data indicate that BAN2401 is ...
BioArctic Neuroscience AB has signed an extension of an ongoing research collaboration on immunotherapy for Alzheimer’s disease with Eisai Co., Ltd., Japan.
Today, VINNOVA announced that BioArctic Neuroscience AB was granted 3.5 million SEK for the clinical development of its proprietary product with the indication Treatment of Traumatic ...
Yesterday the FDA granted the request from BioArctic Neuroscience for orphan-drug designation of heparin activated recombinant human Fibroblast Growth Factor 1 (FGF1) in combination with a ...
SpineMedical AB is a 100 percent owned subsidiary to BioArctic Neuroscience AB. The company was founded to bring the new treatment and product for complete spinal ...
BioArctic presented a symposium together with its partner Eisai at the 10th International Conference on Alzheimer´s & Parkinson´s Diseases (AD/PD) in Barcelona March 9 - 13th. ...
Today, FDA approved the first clinical study with BAN2401 in Alzheimer patients. BAN2401 is a humanized monoclonal antibody targeting the toxic protofibrils in Alzheimer´s disease.
...
BioArctic receives 1st milestone payment from Eisai. In December 2007, BioArctic Neuroscience AB signed an exclusive license agreement with Eisai Co., Ltd, where first milestone payment ...
BioArctic s US patent on an Alzheimer vaccine was approved today. BioArctic Neuroscience AB has a proprietary technological platform for immunotherapy against misfolded proteins.
Today, VINNOVA announced that BioArctic Neuroscience AB was granted 1.9 million SEK for development of its proprietary product with the indication Treatment of Traumatic Spinal Cord ...
Stockholm, Sweden, June 3rd, 2009. BioArctic initiates collaboration with GE-Healthcare and Uppsala University on new diagnostics for Alzheimer´s disease. The intention is to create brain imaging ...
BioArctic Neuroscience AB has today been assigned SME status by EMEA. BioArctic is now eligible to benefit from the provisions for administrative and financial assistance laid ...
BioArtic Neuroscience officially opened its new research and office facilities in Stockholm, Sweden. Ewa Björling, Minister of Trade, officially opened the new facility by cutting the ...
BioArctic Neuroscience expands and increases office and lab space with 50%. On Dec 15th 2008 BioArctic moved to a brand new tailor-made site at Warfvinges väg ...
BioArctic Neuroscience is a research company developing new drugs and diagnostics for neurodegenerative disorders. In 2007, a license agreement was signed with Eisai Co., Ltd., Japan, ...